Semaglutide, sold most widely as Ozempic / Wegovy / Rybelsus, is a GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. This guide covers how it works, what a standard course looks like, and how ShiningRX supplies it to trade buyers and consumers in the USA, UK and Australia.
Key takeaways
- Semaglutide is a GLP-1 receptor agonist indicated for type 2 diabetes and chronic weight management.
- Typical dosing: weekly injection titrated monthly from 0.25 mg toward 1.7–2.4 mg.
- Onset is appetite effects within days, weight plateau at 60–68 weeks; effect lasts 7-day half-life, once-weekly dosing.
- Most reported side effects are nausea and other mild, self-limiting reactions.
- Store 2–8 °C cold chain until first use.
Semaglutide at a glance
| Attribute | Detail |
|---|---|
| Drug class | GLP-1 receptor agonist |
| Common brand | Ozempic / Wegovy / Rybelsus |
| Licensed use | type 2 diabetes and chronic weight management |
| Available strengths | 0.25–2.4 mg pen; 3, 7, 14 mg oral |
| Dosage form | prefilled pen / oral tablet |
| Typical onset | appetite effects within days, weight plateau at 60–68 weeks |
| Duration / dosing interval | 7-day half-life, once-weekly dosing |
| Storage | 2–8 °C cold chain until first use |
How Semaglutide works
As a GLP-1 receptor agonist, Semaglutide acts on the pathway that drives type 2 diabetes and chronic weight management. The pharmacological effect is dose-related, which is why prescribers begin at the lowest useful strength and adjust on response rather than starting at the maximum. In practice that means weekly injection titrated monthly from 0.25 mg toward 1.7–2.4 mg
Starting a Semaglutide course
- 1
Clinical assessment
Confirm the indication for type 2 diabetes and chronic weight management, review comorbidities and check the contraindication list before the first dose.
- 2
Initiate at the standard dose
weekly injection titrated monthly from 0.25 mg toward 1.7–2.4 mg
- 3
Review at the first checkpoint
Reassess once the expected onset window of appetite effects within days, weight plateau at 60–68 weeks has passed and document tolerability.
- 4
Titrate or switch
If response is partial and tolerance is good, step up within the licensed range; if tolerance is poor, consider Tirzepatide.
Safety profile in brief
Commonly reported effects include nausea, constipation, reflux, fatigue, gallbladder events. Semaglutide should be avoided in personal or family history of medullary thyroid carcinoma or MEN2. Any severe, persistent or unexpected reaction warrants stopping the medicine and seeking clinical review.
